Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis

In the original short treatment regimen for rifampicin-resistant tuberculosis, bedaquiline proved an adequate core drug for fluoroquinolone resistance, ensuring early conversion and relapse-free cure. Use of linezolid did not have the same early effect. https://bit.ly/3gWuf9z

Detalles Bibliográficos
Autores principales: Decroo, Tom, Aung, Kya Jai Maug, Hossain, Mohamed Anwar, Gumusboga, Mourad, Ortuno-Gutierrez, Nimer, De Jong, Bouke Catherine, Van Deun, Armand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943272/
https://www.ncbi.nlm.nih.gov/pubmed/34561288
http://dx.doi.org/10.1183/13993003.02124-2021
Descripción
Sumario:In the original short treatment regimen for rifampicin-resistant tuberculosis, bedaquiline proved an adequate core drug for fluoroquinolone resistance, ensuring early conversion and relapse-free cure. Use of linezolid did not have the same early effect. https://bit.ly/3gWuf9z

Ejemplares similares